Navigation Links
New Immune Approach for Treatment of Alzheimer's Disease
Date:6/8/2009

New hope for a much needed new approach for tackling Alzheimer's disease will be discussed in detail this week at a new medical conference in Philadelphia. At the inaugural Targeting Alzheimer's with Novel Therapeutics conference, to be held as part of the 8th annual World Pharmaceutical Congress, Edward Tobinick MD, Director of the Institute for Neurological Research, a private medical group, inc. in Los Angeles, will present the latest data on a revolutionary new immune approach for treatment of Alzheimer's disease.

Los Angeles, CA (PRWEB) June 8, 2009 -- New hope for a much needed new approach for tackling Alzheimer's disease will be discussed in detail this week at the inaugural Targeting Alzheimer's with Novel Therapeutics conference, to be held as part of the 8th annual World Pharmaceutical Congress in Philadelphia on June 10 and 11. On the second day of this conference, after presentations by researchers from Abbott Laboratories, Medivation, Epix Pharmaceuticals, the Buck Institute, Cleveland Clinic, and others, Edward Tobinick MD, Director of the Institute for Neurological Research® (INR®), a private medical group, inc. in Los Angeles, will present the latest data on a revolutionary new immune approach for treatment of Alzheimer's disease.

Dr. Tobinick's presentation, entitled TNF modulation for treatment of Alzheimer's Disease, will review the remarkable results which have been documented using perispinal administration of etanercept, a therapeutic developed through recombinant DNA biotechnology, for treatment of Alzheimer's disease (1-7). This patented (8) off-label treatment method, invented and developed at the INR, may produce clinical improvement within minutes (1-6).

Localized administration of etanercept for treatment of neurological disorders is a novel concept which was invented by Dr. Tobinick a decade ago (8). The proof-of-concept of these novel methods which Dr. Tobinick invented (8, 9), which include both perispinal and epidural etanercept for treatment of sciatica (see INR sciatica website) (8), are now supported by additional, independent studies from academic centers, including a new randomized, double-blind, placebo-controlled clinical trial from Johns Hopkins and Walter Reed Army Medical Center (10, 11).

The prospect of a new, immune-based approach for treatment of Alzheimer's is exciting. Recent reports of the ability of etanercept to penetrate rapidly into the cerebrospinal fluid within the brain in animal studies now provide new insight into the potential mechanisms underlying the rapid clinical effects of etanercept in patients with Alzheimer's disease (12). Patient treatment is currently available at the Institute in Los Angeles, and at the Institute's new office in Newport Beach, California. Further information is available on the website of the INR, at Institute for Neurological Research in Los Angeles website.

References

1. Tobinick, E., Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today, 2009. 14(3-4): p. 168-77.
2. Tobinick, E.L. and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol, 2008. 8: p. 27.
3. Tobinick, E.L. and H. Gross, Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation, 2008. 5: p. 2.
4. Griffin, W.S., Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation, 2008. 5: p. 3.
5. Tobinick, E., Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res, 2007. 4(5): p. 550-2.
6. Tobinick, E., H. Gross, A. Weinberger, and H. Cohen, TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed, 2006. 8(2): p. 25.
7. McAlpine, F.E. and M.G. Tansey, Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's. J Inflammation Research, 2008. 1: p. 29-39.
8. U.S. patents 6,015,557; 6,177,077; 6,419,944; 6,537,549; 6,982,089; 7,214,658, and Australian patent 758,523 issued to Edward Tobinick MD and assigned to TACT IP, LLC, and additional patents and related applications, assigned to TACT IP, LLC.
9. Tobinick, E. and S. Davoodifar, Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin, 2004. 20(7): p. 1075-85.
10. Cohen, S.P., N. Bogduk, A. Dragovich, C.C. Buckenmaier, 3rd, S. Griffith, C. Kurihara, J. Raymond, P.J. Richter, N. Williams, and T.L. Yaksh, Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology, 2009. 110(5): p. 1116-26.
11. Kato, K., S. Kikuchi, V.I. Shubayev, and R.R. Myers, Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve. Neuroscience, 2009. 160(2): p. 492-500.
12. Tobinick, E.L., K. Chen, and X. Chen, Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes, 2009. 2: p. 28.

# # #

Read the full story at http://www.prweb.com/releases/etanercept/alzheimers/prweb2507234.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. Immune deficiency linked to a type of eye cancer
3. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
4. Melanoma drug revs immune cells but cancer cells ignore it
5. Study identifies key player in the bodys immune response to chronic stress
6. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
7. UVA researchers find important clue to immune infertility
8. M.D. Anderson-led team reports possible key to autoimmune disease
9. Their immune cells, fighting your cancer
10. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
11. Occupational exposures may be linked to death from autoimmune disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... Focused ... innovation in the industry, according to the recent NEJM Catalyst Insights Report on ... of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow solution provider ... 20 – 22 in San Francisco. As part of the Tri-Conference expo, which ... workflow solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... Vincent J. Angotti has been appointed ... company,s board of directors, effective Monday, March 6, ... experience leading executive and commercial teams at public ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications ... department visit are necessary for long-term opioid use to ... Feb. 16 th edition of The New ... "Emergency physicians see more patients in acute pain than ... Parker , MD, FACEP, president of the American College ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Function, Application, Cancer Type, Technology - Forecast to 2025" report ... ... grow at a CAGR of around 28.6% over the next decade ... Some of the prominent trends that the market is witnessing include ...
Breaking Medicine Technology: